Drug Profile
Ethinylestradiol/drospirenone/levomefolic acid - Bayer
Alternative Names: BAY98-7071; Beyaz; EE20/DRSP/L-5MTHF; ethinylestradiol/drospirenone/methyltetrahydrofolate; Safyral; Yasmin Plus; Yaz Flex Plus; Yaz PlusLatest Information Update: 22 Mar 2022
Price :
$50
*
At a glance
- Originator Bayer
- Class Alkylated estrogenic steroids; Androstenes; Antiandrogens; Estradiol congeners; Estrenes; Folic acids; Hormonal contraceptives; Norpregnatrienes; Oral contraceptives; Progesterone congeners; Vitamins
- Mechanism of Action Estrogen receptor agonists; Mineralocorticoid receptor antagonists; Progesterone receptor agonists; Testosterone congener inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Acne vulgaris; Pregnancy; Premenstrual dysphoric disorder
Most Recent Events
- 22 Mar 2022 Discontinued - Phase-III for Pregnancy (Prevention) in Mexico (PO)
- 16 Aug 2019 No development reported - Phase-III for Pregnancy (Prevention) in Mexico (PO)
- 20 Jul 2015 No recent reports on development identified - Preregistration for Pregnancy (Prevention) in Europe (PO)